Industry: Healthcare | Publish Date: 23-Jul-2020 | No of Pages: 357 | No. of Tables: 202 | No. of Figures: 172 | Format: PDF | Report Code : N/A
The global Hemodialysis Market size was valued at USD 78.30 billion in 2019, and is predicted to hit USD 116.66 billion by 2030, witnessing a CAGR of 3.60% from 2020-2030.
Hemodialysis is an extra-corporeal renal replacement procedure that aids blood purification by removing of toxins, creatinine, urea, and excess water from blood, utilizing an artificial membrane, hence maintaining the electrolyte balance of the blood.
At the point when kidney functioning goes below 10%-15%, it is unable to filter blood naturally. This enables the toxins to develop in the body alongside excess fluid. Hemodialysis helps evacuate these toxins and is an effective treatment for end-stage renal disease. It is performed at a frequency of 3 times per week, 6 days per week or 3-6 nights per week based on the condition of the patient.
Hemodialysis is performed using a hemodialyzer in hospitals or dialysis centers, and it may be an in-patient or an out-patient treatment. It is used in the treatment of chronic kidney disease, and acute renal injury, for those expecting a kidney transplant or as a permanent measure in cases where a kidney transplant is not advisable.
According to the data reported by World Health Organization, 2.62 million people received in 2010, and the need for dialysis is projected to double by the year 2030. This scenario is propagating the growth of the global hemodialysis market.
Besides, factors such as increasing incidences of renal dysfunction, kidney failures, chronic kidney disease and growing number of end-stage renal disease (ESRD) patients, are likely to propel the growth of the hemodialysis market throughout the forecast period.
Furthermore, increased occurrence of diabetes and hypertension, as well as shortage of kidney donors, are increasing the demand for hemodialysis treatment, hence supplementing the growth of the hemodialysis market.
However, high-cost of the treatment, risks & complications associated with dialysis procedure and product recall are the factors hampering the growth of the hemodialysis market.
Moreover, higher investments in R&D activities, increase in funding for better dialysis products and services, as well as the technological advancements leading to better adoption and growth opportunities in emerging economies shall create lucrative opportunities for growth in the global hemodialysis market in coming future.
The hemodialysis market share has been analyzed on product & service, type, end user, and geography.
Based on product & service, the market is segmented into equipment, consumable, drug, and service. Based on type, the market covers conventional, daily, and nocturnal. Based on the end user, the market is classified into in-center dialysis and home dialysis. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
North America region demonstrates higher adoption of hemodialysis treatment, hence it is expected to dominate the global hemodialysis market, accounting for the highest market share, throughout the forecast period. This is due to presence of well-established healthcare-infrastructure, presence of key market players, introduction to new technologies & innovations as well as higher prevalence of kidney diseases in this region.
Asia Pacific region is expected to grow with the highest CAGR values in the global hemodialysis market throughout the forecast period, owing to higher investments in R&D activities, increasing awareness in diagnosis of kidney diseases at an early stage, and untapped market opportunities in the emerging economies present in this region.
Comprehensive competitive analysis and profiles of the major market players such as Asahi Kasei Corporation, Cantel Medical Corp., DaVita, Inc., Diaverum, Fresenius Medical Care AG & Co. KGaA, Nikkiso Co., Ltd., B. Braun Melsungen AG, Baxter International, Inc., Nipro Corporation, NxStage Medical, Inc., and others are provided in the hemodialysis industry report.
An upsurge in R&D activities, advancement in product technologies along with new product launches, expansions, and acquisitions by the key players, is leading the healthcare infrastructure to new heights, thereby creating lucrative opportunities in the global hemodialysis market.
For instance, in October 2019, one of the key players of the global Hemodialysis market, Diaverum announced its acquisition over INEDI (Instituto de Nefrologia e Diálise Ltda), based in Taboão da Serra in greater São Paulo, Brazil. With this, Diaverum plans to operate its eight renal care centers, treating more than 3,000 patients in Brazil. INEDI is a well-known renal care center with proven record of accomplishment for high treatment volume, strict quality standards, along with commitment & innovation for the patients. This acquisition reinforces Diaverum’s strategy to acquire high-standard treatment centers in the market with potential for continued growth, hence contributing to the local nephrologist community in providing finest renal care to the patients.
Furthermore, in April 2020, the very well-known player of the global hemodialysis market, Baxter International Inc., announced its achievement of receiving emergency use authorization (EUA) from the U.S. FDA, for its ‘Oxiris filter set’ to treat patients suffering from novel corona disease, who are admitted to the intensive care unit (ICU), and are in need of continuous renal replacement therapy (CRRT). The patient’s blood flows into the Oxiris filter set, where endotoxin, cytokines, uremic toxins, and excess fluids are removed from the blood, and purified blood returns to the patient’s body. Oxiris is a multi-purpose filter set that can perform several blood-purification therapies at the same time, including cytokine removal and continuous renal replacement therapy.
The hemodialysis market report provides a quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on.
The study comprises a deep dive analysis of the market trend including the current and future market trends for depicting the prevalent investment pockets in the market
The report provides detailed information related to key drivers, restraints, opportunities, and their impact on the market.
The report incorporates competitive analysis of the market players along with their market share and market size in the global market.
The SWOT analysis and Porters Five Forces model is elaborated in the study of global market.
Value chain analysis in the hemodialysis market study provides a clear picture of the stakeholders’ roles.
Equipment
Consumable
Drug
Service
Conventional
Daily
Nocturnal
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
India
South Korea
Japan
Australia
Rest of Asia-Pacific
ROW
Saudi Arabia
South Africa
Brazil
Remaining Countries
REPORT SCOPE AND SEGMENTATION:
Parameters |
Details |
Analysis Period |
2019–2030 |
Base Year Considered |
2020 |
Forecast Period |
2020–2030 |
Market Size Estimation |
Billion (USD) |
Market Segmentation |
By Type (Conventional Hemodialysis, Short Daily Hemodialysis, Nocturnal Hemodialysis) By Product & Service (Equipment, Consumables, Drugs, Services) |
Geographical Segmentation |
North America (U.S., Canada, Mexico) Europe (UK, Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of APAC), Rest of the World (Brazil, Saudi Arabia, South Africa, Remaining Countries) |
Companies Profiled |
Asahi Kasei Corporation, Cantel Medical Corp., DaVita, Inc., Diaverum, Fresenius Medical Care AG & Co. KGaA, Nikkiso Co., Ltd., B. Braun Melsungen AG, Baxter International, Inc., Nipro Corporation, NxStage Medical, Inc. |
Asahi Kasei Corporation
Cantel Medical Corp.
DaVita, Inc.
Diaverum
Fresenius Medical Care AG & Co. KGaA
Nikkiso Co., Ltd.
B. Braun Melsungen AG
Baxter International, Inc.
Nipro Corporation
NxStage Medical, Inc.